Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Shionogi: Anti-Flu Agent Rapiacta
February 8, 2010
- Re-Pricing of Tasigna, Sprycel “Appropriate” Mr Isobe
February 8, 2010
- JCR Aims at 20% Share for EPO Biosimilar: President Ashida
February 8, 2010
- Rozerem Recommended for Approval
February 8, 2010
- DSP to Transfer Growth Hormone Business to JCR
February 8, 2010
- PMDA Needs Internal Renovation: Prof. Kami
February 8, 2010
- Pregabalin to Drive Pfizer's Primary Case Business: Mr Harada
February 8, 2010
- Panel on Unapproved Drugs to Hold 1st Meeting
February 8, 2010
- Kyowa Kirin Aims at Pharm. Sales of \225.0 Bil. in FY2012
February 8, 2010
- Medical Fees Up for the 1st Time in 10 Years, But Drug Prices Down 6.5%
February 8, 2010
- Zeria to Overcome NHI Price Cuts through Synergism with Tillotts: President Ibe
February 8, 2010
- Present Scientific Grounds for Combination Drugs
February 8, 2010
- FDA Extends PDUFA Date for Sepracor's STEDESA NDA
February 8, 2010
- Price Cuts for Long-Listed Drugs to Harshly Hit Mochida: President Mochida
February 8, 2010
- Gemzar Recommended for Approval for Breast Cancer
February 8, 2010
- Fluzone High-Dose Approved for Elderly Patients in the US: sanofi-aventis
February 8, 2010
- 1 in 5 Does Not Finish Full-Course Tamiflu Treatment
February 8, 2010
- Takara Bio Accelerates Commercialization of Gene, Cell Therapy
February 8, 2010
- Januvia, Glactiv Ranked No. 1, 2 on Both GP, HP Markets
February 8, 2010
- JSCTR to Certify Clinical Trial Monitors
February 8, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…